Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy
Open Access
- 5 October 2018
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 19 (1) , 197
Abstract
Potential relationship between serum soluble programmed cell death ligand 1 and prognosis of small cell lung cancer is not well explored. The aim of the study was to reveal the prognostic significance of serum soluble programmed cell death ligand 1 in patients with small cell lung cancer. A total of 250 small cell lung cancer patients and 250 controls were included. Research information was obtained from their medical records. Blood samples were collected on admission. Serum concentration of programmed cell death ligand 1 was measured using Enzyme-Linked Immunosorbent Assay. The patients underwent cisplatin-etoposide chemotherapy with a maximum of six cycles. Subsequently, they were followed-up for 12 months, and therapeutic response and cancer death were recorded. Serum concentration of programmed cell death ligand 1 was higher in the patients than in the controls on admission (P < 0.001). After chemotherapy, 112 patients had no response to this therapy. In the 12-month follow up period, 118 patients died due to this cancer. Multivariate Cox regression model revealed that the higher serum concentration of programmed cell death ligand 1 on admission was associated with the higher risk of no response to chemotherapy or cancer caused death (HR: 1.40, 95% CI: 1.05 ~ 1.87; HR: 1.43, 95% CI: 1.08 ~ 1.87). Elevated serum concentration of soluble programmed cell death ligand 1 might be an independent risk factor for non-response to chemotherapy and cancer caused death in small cell lung cancer patients.Keywords
This publication has 44 references indexed in Scilit:
- Increased PD-1 on CD4+CD28− T cell and soluble PD-1 ligand-1 in patients with T2DM: Association with atherosclerotic macrovascular diseasesMetabolism, 2013
- Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myelomaLeukemia, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Soluble B7-H1: Differences in production between dendritic cells and T cellsImmunology Letters, 2012
- Small-cell lung cancerThe Lancet, 2011
- Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell linesCytokine, 2011
- Increased Levels of Tumor-Infiltrating Lymphocytes are Associated with Improved Recurrence-Free Survival in Stage 1A Non-Small-Cell Lung CancerJournal of Surgical Research, 2011
- Treatment options for relapsed small-cell lung cancerAnti-Cancer Drugs, 2007
- The function of programmed cell death 1 and its ligands in regulating autoimmunity and infectionNature Immunology, 2007
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000